UNSPSC 51352422: Desogestrel and ethinyl estradiol

This classification denotes a combination contraceptive drug. The first component of this drug is DESOGESTREL, a therapeutic progestin with the molecular formula C22H30O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81K9V7M3A3, chemically known as 18,19-dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)- but generally known as desogestrel, which bears US NIH Compound Identifier 40973.

UNSPSC 51352422 Desogestrel and ethinyl estradiol, a Commodity code, covers the supply of this oral contraceptive formulation to state and local government health programs, employee health plans, and pharmacy benefit programs. State and local governments procure this specific pharmaceutical product as part of broader generic multi-source pharmaceutical contracts serving Medicaid programs, state employee health plans, and public health clinics. The issuing bodies include state health and human services commissions, multistate cooperative purchasing alliances administering shared contracts across participating states and localities, and state departments of administration managing centralized procurement for government health programs. Vendors supplying under this code must meet FDA manufacturing standards, maintain cGMP and Drug Supply Chain Security Act compliance, hold appropriate insurance coverage, and establish relationships with authorized pharmaceutical wholesalers to deliver products through established supply chains.

Recent activity shows two representative solicitations anchoring procurement strategy in this space. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; the contract term runs two years with optional extensions, and awarded vendors must supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with resulting agreements effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to solicit vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring alternative supply models that bypass traditional pharmacy benefit managers and group purchasing organizations. Geographic activity centers on the Upper Midwest and Texas, with MMCAP's multistate cooperative extending procurement reach across participating states including Oregon, while Texas pursues separate direct-contracting innovation. Multistate cooperative vehicles and state-level RFPs dominate the solicitation landscape under this code.